Format

Send to

Choose Destination
Sleep. 2016 Jun 1;39(6):1253-60. doi: 10.5665/sleep.5846.

Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.

Author information

1
Center for Brain Health, NYU School of Medicine, New York, NY.
2
Division of Pulmonary, Critical Care, and Sleep Medicine, NYU School of Medicine, New York, NY.
3
Department of Neuroscience, JFK Medical Center, Edison, NJ.
4
University of Florida College of Medicine, Jacksonville, FL.
5
Department of Neurology, NYU School of Medicine, New York, NY.
6
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
7
UCL Institute of Neurology, Queen Square, London, UK.
8
Department of Biostatistics, Rutgers School of Public Health, Piscataway, NJ.

Abstract

STUDY OBJECTIVES:

To evaluate the role of orexin-A with respect to cerebrospinal fluid (CSF) Alzheimer disease (AD) biomarkers, and explore its relationship to cognition and sleep characteristics in a group of cognitively normal elderly individuals.

METHODS:

Subjects were recruited from multiple community sources for National Institutes of Health supported studies on normal aging, sleep and CSF biomarkers. Sixty-three participants underwent home monitoring for sleep-disordered breathing, clinical, sleep and cognitive evaluations, as well as a lumbar puncture to obtain CSF. Individuals with medical history or with magnetic resonance imaging evidence of disorders that may affect brain structure or function were excluded. Correlation and linear regression analyses were used to assess the relationship between orexin-A and CSF AD-biomarkers controlling for potential sociodemographic and sleep confounders.

RESULTS:

Levels of orexin-A, amyloid beta 42 (Aβ42), phosphorylated-tau (P-Tau), total-tau (T-Tau), Apolipoprotein E4 status, age, years of education, reported total sleep time, number of awakenings, apnea-hypopnea indices (AHI), excessive daytime sleepiness, and a cognitive battery were analyzed. Subjects were 69.59 ± 8.55 years of age, 57.1% were female, and 30.2% were apolipoprotein E4+. Orexin-A was positively correlated with Aβ42, P-Tau, and T-Tau. The associations between orexin-A and the AD-biomarkers were driven mainly by the relationship between orexin-A and P-Tau and were not influenced by other clinical or sleep characteristics that were available.

CONCLUSIONS:

Orexin-A is associated with increased P-Tau in normal elderly individuals. Increases in orexin-A and P-Tau might be a consequence of the reduction in the proportion of the deeper, more restorative slow wave sleep and rapid eye movement sleep reported with aging.

CLINICAL TRIAL REGISTRATION:

Clinicaltrials.gov registration number NCT01962779.

KEYWORDS:

Alzheimer disease; orexin-A; phosphorylated-tau; sleep

PMID:
26951396
PMCID:
PMC4863214
DOI:
10.5665/sleep.5846
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center